A comprehensive view of Inflammations. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

J&J drops out of hunt for Horizon Therapeutics, leaving Sanofi and Amgen to bid on what may be largest biotech acquisition of 2022; deal would include injectables Tepezza for thyroid eye disease, Krystexxa for chronic gout, Uplizna for autoimmune disease

AstraZeneca signs US$402.0M global licensing agreement with C4XD for its NRF2 activator program; AstraZeneca to oversee development, commercialization of oral treatment for chronic obstructive pulmonary disease, other inflammatory and respiratory diseases

Scientists develop plant-based anti-inflammatory, antioxidant electrospun nanofibers for wound healing efficiency; nanofibers are made with polycaprolactone, gelatin, are loaded with phytochemical quercetin, have bactericidal activity: SRM Institute

Executive Perspective: Pfizer CEO says 2023 will be a pivotal year for the company with up to 10 new drug launches; Pfizer planning to launch five new vaccines, new oncology and immuno-inflammation drugs in the next year

Amgen opens new 245,000 square-foot, nine-story R&D facility in San Francisco, California, with staff of 650; new facility to focus on discovering cancer, inflammatory disease, cardiometabolic disorder therapies

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count